CN106459222A - Mic‑1融合蛋白及其用途 - Google Patents

Mic‑1融合蛋白及其用途 Download PDF

Info

Publication number: CN106459222A
Authority: CN; China
Prior art keywords: seq; mic; serum albumin; human serum; compound
Prior art date: 2014-06-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

CN201580033507.XA

Other languages

English (en)

Chinese (zh)

Inventor

A.C.肖

C.赫格斯特兰德

M.P.B.桑德里尼

S.B.乔根森

H.托格森

K.萨斯-奥鲁姆

S.哈斯特鲁普

K.V.安德森

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-24

Filing date

2015-06-17

Publication date

2017-02-22

2015-06-17 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

2017-02-22 Publication of CN106459222A publication Critical patent/CN106459222A/zh

Status Withdrawn legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CN201580033507.XA 2014-06-24 2015-06-17 Mic‑1融合蛋白及其用途 Withdrawn CN106459222A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP14173664		2014-06-24
EP14173664.5		2014-06-24
PCT/EP2015/063596 WO2015197446A1 (en)	2014-06-24	2015-06-17	Mic-1 fusion proteins and uses thereof

Publications (1)

Publication Number	Publication Date
CN106459222A true CN106459222A (zh)	2017-02-22

Family

ID=51032955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201580033507.XA Withdrawn CN106459222A (zh)	2014-06-24	2015-06-17	Mic‑1融合蛋白及其用途

Country Status (15)

Country	Link
US (2)	US9272019B2 (2)
EP (1)	EP3160496B1 (2)
JP (1)	JP6696915B2 (2)
KR (1)	KR20170020383A (2)
CN (1)	CN106459222A (2)
AR (1)	AR100945A1 (2)
AU (1)	AU2015279525A1 (2)
BR (1)	BR112016029848A2 (2)
CA (1)	CA2952293A1 (2)
IL (1)	IL249327A0 (2)
MX (1)	MX2016016063A (2)
RU (1)	RU2017101436A (2)
TW (1)	TW201613958A (2)
WO (1)	WO2015197446A1 (2)
ZA (1)	ZA201608214B (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110770251A (zh) *	2017-04-20	2020-02-07	诺和诺德股份有限公司	纯化白蛋白融合蛋白的方法
WO2022089435A1 (en) *	2020-10-27	2022-05-05	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion proteins of gdf15 and use thereof

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2694092B1 (en)	2011-04-08	2017-01-04	Amgen Inc.	Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US9862752B2 (en)	2013-07-31	2018-01-09	Amgen Inc.	Growth differentiation factor 15 (GDF-15) constructs
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
JP6946304B2 (ja)	2015-12-22	2021-10-06	ノバルティスアーゲー	増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) *	2016-05-10	2019-07-02	Janssen Biotech, Inc.	GDF15 fusion proteins and uses thereof
KR102433503B1 (ko) *	2016-05-24	2022-08-18	노보 노르디스크 에이/에스	Mic-1 화합물 및 이것의 사용
GB201615844D0 (en) *	2016-09-16	2016-11-02	Genagon Therapeutics Ab	Agents for use in therapy
US20200069774A1 (en) *	2016-12-06	2020-03-05	St Vincent's Hospital Sydney Limited	Treatment of obesity and eating disorders
GB201700567D0 (en)	2017-01-12	2017-03-01	Genagon Therapeutics Ab	Therapeutic agents
GB201700553D0 (en) *	2017-01-12	2017-03-01	Genagon Therapeutics Ab	Therapeutic agents
TWI710377B (zh)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Ｍｉｃ－１化合物及其用途
CN111163795A (zh)	2017-09-10	2020-05-15	诺沃挪第克公司	用于治疗肥胖症的mic-1和glp-1
US11913039B2 (en)	2018-03-30	2024-02-27	Alexion Pharmaceuticals, Inc.	Method for producing recombinant alkaline phosphatase
TWI724392B (zh)	2018-04-06	2021-04-11	美商美國禮來大藥廠	生長分化因子15促效劑化合物及其使用方法
CR20200510A (es)	2018-04-09	2020-11-26	Amgen Inc	Protreínas de fusión del factor de diferenciación de crecimiento 15
EP3833974A2 (en)	2018-08-10	2021-06-16	Novartis AG	Gfral extracellular domains and methods of use
US12268733B2 (en)	2018-08-10	2025-04-08	Alexion Pharmaceuticals, Inc.	Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EA202191105A1 (ru)	2018-10-22	2021-08-03	Янссен Фармацевтика Нв	Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP4041281B1 (en)	2019-10-04	2025-11-26	Amgen Inc.	Use of gdf15 for treating cardiometabolic syndrome and other conditions
CA3161302A1 (en) *	2019-11-26	2021-06-03	Yuhan Corporation	Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
CA3161266A1 (en) *	2019-12-09	2021-06-17	Alexion Pharmaceuticals, Inc.	Alkaline phosphatase polypeptides and methods of use thereof
CA3159979A1 (en) *	2019-12-11	2021-06-17	Yeonchul Kim	Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
CN115379850A (zh) *	2019-12-24	2022-11-22	裘美娜治疗公司	再生性多肽及其用途
EP4085077A4 (en) *	2019-12-31	2024-01-17	Beijing QL Biopharmaceutical Co., Ltd.	Fusion proteins of glp-1 and gdf15 and conjugates thereof
WO2021194257A1 (ko) *	2020-03-25	2021-09-30	(주) 업테라	세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
KR102195740B1 (ko) *	2020-03-25	2020-12-28	서울대학교산학협력단	세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
AU2021337652B2 (en)	2020-09-04	2025-01-30	Alexion Pharmaceuticals, Inc.	Methods for treating bone mineralization disorders
CN112694520B (zh) *	2020-12-02	2023-01-17	图凌(杭州)生物医药有限公司	一种人工多肽hm、其抗体及在病理检测中的应用
BR112023016048A2 (pt)	2021-02-12	2023-11-14	Alexion Pharma Inc	Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
WO2022219495A1 (en)	2021-04-12	2022-10-20	Novartis Ag	2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
EP4476212A1 (en)	2022-02-10	2024-12-18	Novartis AG	2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
EP4389762A1 (en)	2022-12-23	2024-06-26	Ospedale San Raffaele S.r.l.	Inhibitors of dux4 activity and their use in therapy.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013113008A1 (en) *	2012-01-26	2013-08-01	Amgen Inc.	Growth differentiation factor 15 (gdf-15) polypeptides
WO2013148117A1 (en) *	2012-03-27	2013-10-03	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2213743A1 (en)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albumin fusion proteins
CN1241946C (zh)	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
EP2441466B1 (en)	2004-04-13	2014-07-23	St Vincent's Hospital Sydney Limited	MIC-1 inhibiting agent
EP2194064A1 (en) *	2004-05-13	2010-06-09	Eli Lilly & Company	FGF-21 fusion proteins
EP1771467A2 (en) *	2004-07-26	2007-04-11	Asterion Limited	Linkers
JP2010536341A (ja)	2007-08-15	2010-12-02	アムニクス，インコーポレイテッド	生物学的に活性なポリペプチドの特性を改変するための組成物および方法
KR101993714B1 (ko)	2013-01-30	2019-06-28	엔지엠 바이오파마슈티컬스, 아이엔씨.	대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9862752B2 (en)	2013-07-31	2018-01-09	Amgen Inc.	Growth differentiation factor 15 (GDF-15) constructs

2015
- 2015-06-17 RU RU2017101436A patent/RU2017101436A/ru unknown
- 2015-06-17 MX MX2016016063A patent/MX2016016063A/es unknown
- 2015-06-17 EP EP15730140.9A patent/EP3160496B1/en not_active Withdrawn - After Issue
- 2015-06-17 CA CA2952293A patent/CA2952293A1/en not_active Withdrawn
- 2015-06-17 AU AU2015279525A patent/AU2015279525A1/en not_active Withdrawn
- 2015-06-17 TW TW104119532A patent/TW201613958A/zh unknown
- 2015-06-17 KR KR1020167037059A patent/KR20170020383A/ko not_active Withdrawn
- 2015-06-17 JP JP2016574944A patent/JP6696915B2/ja not_active Expired - Fee Related
- 2015-06-17 BR BR112016029848A patent/BR112016029848A2/pt not_active Application Discontinuation
- 2015-06-17 CN CN201580033507.XA patent/CN106459222A/zh not_active Withdrawn
- 2015-06-17 WO PCT/EP2015/063596 patent/WO2015197446A1/en not_active Ceased
- 2015-06-17 US US14/742,159 patent/US9272019B2/en not_active Expired - Fee Related
- 2015-06-23 AR ARP150102007A patent/AR100945A1/es active IP Right Grant
2016
- 2016-01-19 US US15/000,637 patent/US9956264B2/en not_active Expired - Fee Related
- 2016-11-28 ZA ZA2016/08214A patent/ZA201608214B/en unknown
- 2016-12-01 IL IL249327A patent/IL249327A0/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013113008A1 (en) *	2012-01-26	2013-08-01	Amgen Inc.	Growth differentiation factor 15 (gdf-15) polypeptides
WO2013148117A1 (en) *	2012-03-27	2013-10-03	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RYOICHI ARAI等: "Design of the linkers which effectively separate domains of a bifunctional fusion protein", 《PROTEIN ENGINEERING》 *
XIAOYING CHEN等: "Fusion protein linkers: property, design and functionality", 《ADV DRUG DELIV REV.》 *
ZHIHAO LU等: "Change of body weight and macrophage inhibitory cytokine-1 during chemotherapy in advanced gastric cancer: what is their clinical significance?", 《PLOS ONE》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110770251A (zh) *	2017-04-20	2020-02-07	诺和诺德股份有限公司	纯化白蛋白融合蛋白的方法
WO2022089435A1 (en) *	2020-10-27	2022-05-05	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion proteins of gdf15 and use thereof
US11884711B2 (en)	2020-10-27	2024-01-30	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion proteins of GDF15 and use thereof

Also Published As

Publication number	Publication date
RU2017101436A (ru)	2018-07-24
TW201613958A (en)	2016-04-16
CA2952293A1 (en)	2015-12-30
JP2017528419A (ja)	2017-09-28
BR112016029848A2 (pt)	2017-10-24
WO2015197446A1 (en)	2015-12-30
MX2016016063A (es)	2017-03-10
RU2017101436A3 (2)	2019-02-13
EP3160496B1 (en)	2021-03-03
EP3160496A1 (en)	2017-05-03
AU2015279525A1 (en)	2016-12-15
JP6696915B2 (ja)	2020-05-20
US9956264B2 (en)	2018-05-01
US20160129083A1 (en)	2016-05-12
US20160015784A1 (en)	2016-01-21
US9272019B2 (en)	2016-03-01
ZA201608214B (en)	2018-11-28
KR20170020383A (ko)	2017-02-22
AR100945A1 (es)	2016-11-09
IL249327A0 (en)	2017-02-28

Legal Events

Date	Code	Title	Description
2017-02-22	C06	Publication
2017-02-22	PB01	Publication
2017-06-23	SE01	Entry into force of request for substantive examination
2017-06-23	SE01	Entry into force of request for substantive examination
2021-03-19	WW01	Invention patent application withdrawn after publication
2021-03-19	WW01	Invention patent application withdrawn after publication	Application publication date: 20170222

Publication	Publication Date	Title
US9956264B2 (en)	2018-05-01	MIC-1 fusion proteins and uses thereof
US12006344B2 (en)	2024-06-11	MIC-1 compounds and use thereof
US8741841B2 (en)	2014-06-03	Fibroblast growth factor 21 proteins
KR102085605B1 (ko)	2020-03-06	대사 장애를 치료하기 위한 융합 단백질
JP6110304B2 (ja)	2017-04-05	Ｆｇｆ２１関連障害を処置する方法
EP2764019B1 (en)	2019-04-03	Dual function proteins for treating metabolic disorders
CN107108754A (zh)	2017-08-29	α‑1‑抗胰蛋白酶(A1AT)融合蛋白及其用途
KR20240126875A (ko)	2024-08-21	Glp-1과 gdf15의 융합 단백질 및 이의 용도
RU2776529C2 (ru)	2022-07-21	Соединения mic-1 и их применение